| Variant Name | Allele Count | Allele Frequency | Associated Disease | Associated Gene |
|---|---|---|---|---|
| NM_000771.4:c.1075A>C | 9 | |||
| NM_000771.3:c.430C>T | 9 |
| Subject Id | Country | HPO Terms | Sex | Family History | Parental Consanguinity | Remarks |
|---|---|---|---|---|---|---|
| 122700.G.2.1 | Lebanon | No | 106 out of 231 total subjects. 21 heterozygous subjects were used to determine the effects of variants on Warfarin and Acenocoumarol dosage, which was significantly higher than AA carriers. Studies on groups of alleles were performed [see Esmerian et al. 2011] | |||
| 122700.G.2.2 | Lebanon | 68 out of 231 total subjects. 13 homozygous subjects were used to determine the effects of variants on Warfarin and Acenocoumarol dosage, which was significantly lower than GA and GG carriers. | ||||
| 122700.G.2.3 | Lebanon | 52 out of 231 total subjects | ||||
| 122700.G.2.4 | Lebanon | 23 out of 231 total subjects. Allele carriers of this variant had a significantly lower dosage of warfarin compared to wild type. | ||||
| 122700.G.2.5 | Lebanon | 5 out of 231 total subjects |